FUTURA BIOLABS
A comprehensive A–Z reference for peptide research terminology. For in-vitro laboratory research use only.
Amino Acid
The building blocks of peptides and proteins. Each amino acid consists of an amino group (–NH₂), a carboxyl group (–COOH), and a unique side chain (R group). There are 20 standard amino acids encoded by the genetic code.
Acetic Acid (Dilute)
A mild acid (typically 0.1% aqueous solution) used as a reconstitution solvent for hydrophobic peptides that do not dissolve readily in bacteriostatic water. Creates a slightly acidic environment that aids dissolution without denaturing the peptide.
Angiogenesis
The formation of new blood vessels from pre-existing vasculature. Several research peptides, including BPC-157 and TB-500, have been studied for their role in promoting angiogenesis in preclinical tissue injury models.
Amphipathic
A structural property of molecules possessing both hydrophilic and hydrophobic regions. Many biologically active peptides are amphipathic, which influences their interaction with cell membranes and protein targets.
AOD-9604
A 16-amino acid synthetic fragment of the C-terminus of human growth hormone (hGH, residues 176–191), modified to prevent GH receptor binding. Studied in metabolic research for its lipolytic properties independent of IGF-1 stimulation.
Bacteriostatic Water
Sterile water for injection containing 0.9% benzyl alcohol as a preservative. The benzyl alcohol inhibits bacterial growth, allowing multi-dose use of a reconstituted vial over 28 days when stored correctly at 2–8°C. The standard solvent for most research peptides.
Bioavailability
The proportion of an administered compound that reaches systemic circulation in an unchanged, active form. Peptides are generally poor oral bioavailability candidates due to enzymatic degradation in the GI tract; most research protocols employ subcutaneous or intramuscular administration routes.
BPC-157
Body Protection Compound-157. A 15-amino acid synthetic pentadecapeptide derived from a partial sequence of body protection compound (BPC) originally isolated from human gastric juice. Extensively studied in preclinical models for its tissue-protective and repair-promoting properties.
C-Terminus
The end of a peptide or protein chain that carries a free carboxyl group (–COOH). Conventionally written on the right in peptide sequence notation. Important in defining peptide orientation and receptor binding interactions.
Certificate of Analysis (CoA)
A quality assurance document provided by the manufacturer or third-party testing laboratory confirming the identity, purity, and specifications of a peptide compound. Should include HPLC purity percentage, mass spectrometry confirmation, batch number, and storage recommendations.
CJC-1295
A synthetic analogue of growth hormone-releasing hormone (GHRH), modified at several residues to resist enzymatic degradation. The DAC (Drug Affinity Complex) formulation incorporates a lysine-maleimide group that binds serum albumin, extending plasma half-life from minutes to several days in animal models.
Concentration
The amount of solute (peptide) per unit volume of solution. In peptide research, typically expressed as mcg/mL (micrograms per millilitre) or mg/mL (milligrams per millilitre). Calculated as: Concentration = peptide amount (mg) ÷ solvent volume (mL).
Cyclic Peptide
A peptide in which the N-terminus and C-terminus are joined by a peptide bond, or in which a side-chain forms an intramolecular bond creating a ring structure. Cyclic peptides generally exhibit greater proteolytic stability than linear peptides.
Disulfide Bond
A covalent bond formed between the sulfur atoms of two cysteine residues (–S–S–). Disulfide bonds contribute significantly to peptide tertiary structure and stability. AOD-9604 contains cysteine residues that can form an intramolecular disulfide bridge.
Dissolution
The process by which a solid (lyophilised peptide powder) disperses into a solvent to form a homogeneous solution. Peptide dissolution rate is influenced by factors including pH, temperature, solvent polarity, peptide hydrophobicity, and molecular size.
DAC (Drug Affinity Complex)
A chemical modification technology applied to CJC-1295 that incorporates a reactive maleimide group enabling covalent binding to serum albumin. This dramatically extends circulating half-life and enables sustained GH secretion profiles in research models.
Endogenous Peptide
A peptide naturally produced within a living organism. Research peptides are typically synthetic analogues or fragments of endogenous peptides, engineered to improve stability, potency, or selectivity compared to their native counterparts.
Enzymatic Degradation
The breakdown of peptides by proteolytic enzymes (proteases or peptidases). Endogenous proteases in plasma and tissues rapidly degrade most unmodified peptides. Research-grade synthetic peptides often incorporate non-natural amino acids or chemical modifications to resist enzymatic cleavage.
Fragment (Peptide)
A shorter peptide sequence derived from a larger parent protein or peptide. AOD-9604 is a fragment of human growth hormone. Fragments often retain specific biological activities of the parent molecule while eliminating unwanted effects.
Freeze-Drying (Lyophilisation)
A preservation technique in which material is first frozen and then subjected to reduced pressure, causing the frozen water to sublimate (transition directly from ice to vapour). Produces a dry, stable, lyophilised powder with extended shelf life.
GHRH (Growth Hormone-Releasing Hormone)
An endogenous hypothalamic peptide that stimulates the pituitary gland to produce and secrete growth hormone. CJC-1295 is a synthetic GHRH analogue designed to amplify and prolong natural GH pulsatile release.
GH Secretagogue
A compound that stimulates the secretion of growth hormone. Ipamorelin is a third-generation GH secretagogue that acts via the ghrelin receptor (GHSR-1a) with high selectivity for GH release and minimal impact on cortisol, prolactin, or ACTH.
Ghrelin Mimetic
A compound that mimics the action of ghrelin (the 'hunger hormone') at the GHSR-1a receptor. Ipamorelin is a ghrelin mimetic that selectively stimulates GH secretion without replicating ghrelin's orexigenic (appetite-stimulating) effects.
Half-Life
The time required for the concentration of a compound in circulation to decrease by 50%. Unmodified peptides typically have short plasma half-lives (minutes). Chemical modifications (e.g., DAC in CJC-1295) or formulation strategies can dramatically extend half-life for research purposes.
HPLC (High-Performance Liquid Chromatography)
The gold-standard analytical technique for determining peptide purity. Separates mixture components by differential interaction with a stationary phase. Results in a chromatogram where the target peptide peak area relative to total peak area defines purity percentage.
Hydrophilic
Water-attracting. Hydrophilic peptides contain a predominance of polar or charged amino acid residues and dissolve readily in aqueous solvents including bacteriostatic water. Most research peptides are sufficiently hydrophilic for standard reconstitution.
Hydrophobic
Water-repelling. Hydrophobic peptides contain a predominance of non-polar amino acid residues. May require alternative solvents such as dilute acetic acid or DMSO for initial dissolution before dilution with aqueous buffer.
IGF-1 (Insulin-like Growth Factor-1)
A growth factor produced primarily in the liver in response to GH stimulation. IGF-1 mediates many of GH's anabolic and growth-promoting effects. CJC-1295 increases IGF-1 levels in animal models; AOD-9604 is specifically designed to avoid IGF-1 stimulation.
Ipamorelin
A synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) and third-generation growth hormone secretagogue. Distinguished by its high selectivity for GH release — it does not significantly stimulate cortisol, aldosterone, prolactin, or ACTH at research doses.
In Vitro
Latin for 'in glass.' Refers to experiments conducted outside a living organism, typically in cell culture or isolated tissue preparations. All Futura Biolabs research peptides are supplied for in-vitro laboratory research use only.
Lyophilised (Lyophilization)
The state of a substance that has been freeze-dried. Lyophilised peptides are in powder form, stable at −20°C for up to 48 months, and require reconstitution with an appropriate solvent before use in research protocols.
Lipolysis
The enzymatic hydrolysis of triglycerides stored in adipose tissue, releasing free fatty acids and glycerol. AOD-9604 is studied for its ability to stimulate lipolysis in adipocyte cell culture models without the proliferative effects of full-length hGH.
Mass Spectrometry (MS)
An analytical technique that measures the mass-to-charge ratio of ions. Used to confirm peptide identity by determining molecular weight. A CoA should include MS data showing that the observed molecular weight matches the theoretical value of the target peptide (typically within ±1 Da).
Molecular Weight (MW)
The sum of the atomic masses of all atoms in a molecule, expressed in Daltons (Da) or g/mol. The molecular weight of a peptide can be calculated from its amino acid sequence and is used in MS confirmation of identity.
MOTS-c
Mitochondrial ORF of the 12S rRNA type-c. A 16-amino acid peptide encoded within the mitochondrial 12S ribosomal RNA gene — a region previously considered non-coding. Translates within mitochondria and translocates to the nucleus to regulate gene expression, notably activating AMPK.
N-Terminus
The end of a peptide chain bearing a free amino group (–NH₂). Conventionally written on the left in peptide sequence notation. Many peptide modifications, such as acetylation (Ac-) in TB-500, occur at the N-terminus.
Non-Natural Amino Acid
An amino acid not encoded by the standard genetic code. Incorporated into synthetic peptides to improve stability, potency, or receptor selectivity. Examples include D-amino acids (mirror images of natural L-amino acids) and Aib (alpha-aminoisobutyric acid) found in Ipamorelin.
Peptide
A short chain of amino acids linked by peptide bonds (–CO–NH–). By convention, peptides contain 2–50 amino acids; longer chains are termed polypeptides or proteins. Peptides are distinguished from proteins by their smaller size and simpler secondary/tertiary structure.
Peptide Bond
The covalent amide bond (–CO–NH–) formed between the carboxyl group of one amino acid and the amino group of another, with the release of a water molecule (condensation reaction). The backbone of all peptide and protein structures.
Proteolysis
The hydrolytic cleavage of peptide bonds by proteolytic enzymes (proteases). A primary degradation pathway for peptide compounds in biological systems. Research-grade peptides are typically modified to enhance proteolytic resistance.
Purity
The proportion of the desired peptide compound in a sample, expressed as a percentage. Futura Biolabs supplies peptides at ≥99% HPLC purity, verified by third-party testing. Purity directly impacts research reproducibility and data reliability.
Reconstitution
The process of dissolving a lyophilised peptide powder into a liquid solvent (typically bacteriostatic water) to produce a solution suitable for research use. Key variables include solvent choice, volume added, temperature, and mixing technique.
Research Use Only (RUO)
A regulatory designation indicating that a product is intended exclusively for laboratory research purposes and is not approved for use in humans, animals, or clinical applications. All Futura Biolabs peptides are supplied as RUO compounds.
Sequence
The specific linear order of amino acids in a peptide chain, read from N-terminus (left) to C-terminus (right). The sequence fully determines a peptide's primary structure and, together with its modifications, defines its chemical identity.
SPPS (Solid-Phase Peptide Synthesis)
The predominant method for manufacturing synthetic peptides. Amino acids are sequentially added to a resin-bound growing chain. After assembly, the peptide is cleaved from the resin and purified via HPLC. SPPS enables incorporation of non-natural amino acids and precise control of sequence.
Subcutaneous (SC) Administration
Injection into the subcutaneous tissue layer beneath the skin. A common route of administration in animal model research for peptides due to acceptable bioavailability and minimised systemic trauma.
TB-500
A synthetic analogue of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid protein involved in actin regulation and cellular migration. The TB-500 sequence replicates the critical active region of Tβ4, retaining its actin-binding and cell-motility-promoting properties.
Thymosin Beta-4 (Tβ4)
An endogenous 43-amino acid peptide found in virtually all nucleated mammalian cells. Functions as the primary G-actin sequestering protein in the cytoplasm. Plays a key role in cell migration, wound healing, angiogenesis, and anti-inflammatory signalling.
U-100 Insulin Syringe
A syringe calibrated for U-100 insulin (100 units per mL). Commonly used in peptide research for accurate small-volume measurements. A peptide solution at 1,000 mcg/mL reconstituted with 1 mL of solvent would deliver 100 mcg per 10 units on the syringe scale.
Vial
A small sealed glass container used to store lyophilised or reconstituted peptide compounds. Research-grade peptide vials use borosilicate glass with rubber stoppers and aluminium crimp seals. Sterile, single- or multi-dose configurations are used depending on the research protocol.
Zwitterion
A molecule that carries both a positive and a negative charge simultaneously, with an overall net charge of zero. Amino acids exist as zwitterions at physiological pH — the amino group is protonated (–NH₃⁺) and the carboxyl group is deprotonated (–COO⁻). This property influences peptide solubility and behaviour in solution.